Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPensionProperty, Plant & Equipment (Net)Raw MaterialsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fresenius Medical Care AG (FMS) Total Non-Current Liabilities (2016 - 2025)

Fresenius Medical Care AG (FMS) has 15 years of Total Non-Current Liabilities data on record, last reported at $13.0 billion in Q4 2024.

  • For Q4 2024, Total Non-Current Liabilities changed N/A year-over-year to $13.0 billion; the TTM value through Dec 2024 reached $13.0 billion, changed N/A, while the annual FY2024 figure was $13.1 billion, N/A changed from the prior year.
  • Total Non-Current Liabilities reached $13.0 billion in Q4 2024 per FMS's latest filing, down from $14.1 billion in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $15.9 billion in Q4 2020 and bottomed at $13.0 billion in Q4 2024.
  • Average Total Non-Current Liabilities over 4 years is $14.5 billion, with a median of $14.6 billion recorded in 2021.
  • Peak YoY movement for Total Non-Current Liabilities: rose 13.28% in 2020, then fell 6.01% in 2022.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $15.9 billion in 2020, then fell by 5.29% to $15.0 billion in 2021, then fell by 6.01% to $14.1 billion in 2022, then fell by 8.13% to $13.0 billion in 2024.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $13.0 billion in Q4 2024, $14.1 billion in Q4 2022, and $15.0 billion in Q4 2021.